Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor le
| Agency | National Institutes of Health |
|---|---|
| Status | Forecasted |
| Opportunity number | PAR-26-120 |
| Posted date | 02/11/2026 |
| Expected number of awards | 10 |
| Who can apply | Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions). |
| Assistance Listing (CFDA) | 93.394 |
| Description | Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence |
| Agency contact | ncipcdc@nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/361275 |